Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-996-9058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Myomo (NASDAQ:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the NASDAQ under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo, Inc. (NASDAQ:MYO) posted its earnings results on Thursday, August, 8th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The firm had revenue of $0.88 million for the quarter, compared to analysts' expectations of $1.09 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What is the consensus analysts' recommendation for Myomo?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Media coverage about MYO stock has trended somewhat negative on Saturday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myomo earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Myomo.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Resonance Health (RHT), Osprey Medical (OSP), Universal Biosensors (UBI), GI Dynamics (GID), LBT Innovations (LBT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Avacta Group (AVCT), Azure Healthcare (AZV), Anteo Diagnostics (ADO), Aurora Spine (ASG), Surgical Innovations Group (SUN), Total Brain (TTB), Analytica (ALT) and Adherium (ADR).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $0.67.
How big of a company is Myomo?
What is Myomo's official website?
How can I contact Myomo?
The company can be reached via phone at 617-996-9058.
MarketBeat Community Rating for Myomo (NASDAQ MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
